Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Concurrent Chemoradiotherapy in Elderly Esophageal Squamous Cell Carcinoma
NCT06988956Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2024
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 100 months. Started Mar 2024; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06988956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988956.